Predictions
Pfizer Inc.
Start price
Target price
Perf. (%)
€33.21
08.07.21
08.07.21
€55.00
08.07.22
08.07.22
29.12%
18.02.22
18.02.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
Johnson & Johnson
Start price
Target price
Perf. (%)
€142.86
08.07.21
08.07.21
€177.00
08.07.22
08.07.22
22.71%
08.07.22
08.07.22
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€312.30
02.04.21
02.04.21
-
02.04.22
02.04.22
14.06%
27.08.21
27.08.21
Johnson & Johnson
Start price
Target price
Perf. (%)
€136.62
24.03.21
24.03.21
€145.00
24.03.22
24.03.22
-1.26%
09.04.21
09.04.21
Known brand
Future proof or reliable business model
Medium risks for its business
Johnson & Johnson
Start price
Target price
Perf. (%)
€135.56
16.03.21
16.03.21
€140.00
-0.53%
23.03.21
23.03.21
Known brand
Future proof or reliable business model
Medium risks for its business
Pfizer Inc.
Start price
Target price
Perf. (%)
€29.35
15.03.21
15.03.21
€50.00
15.03.22
15.03.22
43.43%
09.11.21
09.11.21
Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
Johnson & Johnson
Start price
Target price
Perf. (%)
€137.96
08.02.21
08.02.21
€160.00
08.02.22
08.02.22
8.94%
08.02.22
08.02.22
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€271.85
08.02.21
08.02.21
-
08.02.22
08.02.22
-1.91%
20.02.21
20.02.21
Johnson & Johnson
Start price
Target price
Perf. (%)
€138.90
05.02.21
05.02.21
-
31.12.21
31.12.21
0.09%
29.03.21
29.03.21
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Fair valuation
Innovative
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€274.60
29.01.21
29.01.21
€300.00
29.01.22
29.01.22
52.59%
30.01.22
30.01.22
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€282.25
28.01.21
28.01.21
€350.00
28.01.22
28.01.22
22.16%
02.07.21
02.07.21
Johnson & Johnson
Start price
Target price
Perf. (%)
€134.68
20.01.21
20.01.21
€144.00
0.89%
02.02.21
02.02.21
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Fair valuation
Innovative